Characteristics | Total | No. patients (%) | P | No. patients (%) | P | ||
---|---|---|---|---|---|---|---|
CTC Count at baseline | CTC Count at baseline | ||||||
≥1 | <1 | ≥5 | <5 | ||||
Overall | 60 | 27 (45.0) | 33 (55.0) | Â | 12 (20.0) | 48 (80.0) | Â |
Age (years) | Â | Â | Â | Â | Â | Â | Â |
  Mean | 48.8 | 46.6 | 50.6 | 0.155 | 46.6 | 49.4 | 0.420 |
  Range | 25-75 | 25-68 | 33-75 | 25-58 | 32-75 | ||
Histology | Â | Â | Â | Â | Â | Â | Â |
  Ductal | 49 | 24 (49.0) | 25 (51.0) | 0.130 | 10 (20.4) | 39 (79.6) | 0.481 |
  Lobular | 3 | 0 (0.0) | 3 (100.0) | 0 (0.0) | 3 (100.0) | ||
  Others | 8 | 3 (37.5) | 5 (62.5) | 2 (25.0) | 6 (75.0) | ||
ER | Â | Â | Â | Â | Â | Â | Â |
  Positive | 24 | 9 (37.5) | 15 (62.5) | 0.430 | 4 (16.7) | 20 (83.3) | 0.746 |
  Negative | 36 | 18 (50.0) | 18 (50.0) | 8 (22.2) | 28 (77.8) | ||
PR | Â | Â | Â | Â | Â | Â | Â |
  Positive | 22 | 9 (40.9) | 13 (59.1) | 0.789 | 4 (18.2) | 18 (81.8) | 1.000 |
  Negative | 38 | 18 (47.4) | 20 (52.6) | 8 (21.1) | 30 (78.9) | ||
No. of Metastasis | Â | Â | Â | Â | Â | Â | Â |
  1 | 19 | 5 (26.3) | 14 (73.7) | 0.057 | 1 (5.3) | 18 (94.7) | 0.082 |
  ≥2 | 41 | 22 (53.7) | 19 (46.3) | 11 (26.8) | 30 (73.2) | ||
Metastatic sites | Â | Â | Â | Â | Â | Â | Â |
  Bone only | 4 | 2 (50.0) | 2 (50.0) | 0.314 | 0 (0.0) | 4 (100.0) | 0.270 |
  Visceral only | 7 | 2 (28.6) | 5 (71.4) | 1 (14.3) | 6 (85.7) | ||
  Bone and visceral | 30 | 18 (60.0) | 12 (40.0) | 8 (26.7) | 22 (73.3) | ||
DFS | Â | Â | Â | Â | Â | Â | Â |
  ≤12 months | 11 | 3 (27.3) | 8 (72.7) | 0.306 | 3 (27.3) | 8 (72.7) | 0.671 |
  >12 months | 39 | 19 (48.7) | 20 (51.3) | 7 (17.9) | 32 (82.1) | ||
Therapy line | Â | Â | Â | Â | Â | Â | Â |
  1 | 15 | 7 (46.7) | 8 (53.3) | 0.470 | 3 (20.0) | 12 (80.0) | 0.329 |
  2 | 9 | 2 (22.2) | 7 (77.8) | 1 (11.1) | 8 (88.9) | ||
  3 | 13 | 7 (53.8) | 6 (46.2) | 1 (7.7) | 12 (92.3) | ||
  ≥ 4 | 23 | 11 (47.8) | 12 (52.2) | 7 (30.4) | 16 (69.6) |